| Identification | Back Directory | [Name]
AZD2906 | [CAS]
1034148-15-6 | [Synonyms]
AZD2906
AZD2906,AZD-2906
Cyclopropanecarboxamide, N-[(1R,2S)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(6-methoxy-3-pyridinyl)-1-methylethyl]-, rel- | [Molecular Formula]
C26H25FN4O3 | [MOL File]
1034148-15-6.mol | [Molecular Weight]
460.5 |
| Chemical Properties | Back Directory | [Boiling point ]
651.4±55.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (271.44 mM) | [form ]
Solid | [pka]
15.03±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively[1]. | [in vivo]
AZD2906 (5, 25, 50 mg/kg, p.o.) increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats after treatment for 2 days[1].
AZD2906 (5, 25 mg/kg, p.o.) induces an accumulation of glycogen in the liver of rats, and exhibits cortical lymphocytic atrophy of a moderate to marked degree in the thymus of rats[1]. | Animal Model: | Male Wistar Han rats (10 weeks old)[1] | | Dosage: | 5, 25, 50 mg/kg | | Administration: | P.O. for 2 days | | Result: | Caused significant increase in micronucleated immature erythrocytes (MIE) at all doses after analysis of the standard 2000 IE. |
| [References]
[1] Hayes JE, et al. Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. I: glucocorticoid receptor agonism. Mutagenesis. 2013 Mar;28(2):227-32. DOI:10.1093/mutage/ges076 |
|
|